What is Cagent Vascular?
Cagent Vascular Inc. is dedicated to revolutionizing cardiovascular interventions through its proprietary Serration Technology, which is integrated into innovative angioplasty balloons. Their flagship product, the Serranator, is engineered to improve lumen gain and minimize procedural complications, thereby setting a new benchmark in vascular treatments. The company's focus on enhancing patient outcomes and quality of life for individuals with cardiovascular conditions positions it as a key player in the medical technology sector. The company's funding trajectory indicates a strong growth phase, moving from early-stage development to scaling its innovative solutions.
How much funding has Cagent Vascular raised?
Cagent Vascular has raised a total of $90.5M across 6 funding rounds:
Series B
$11.9M
Debt
$150K
Private Equity
$9M
Series C
$30M
Private Equity
$15M
Private Equity
$24.5M
Series B (2018): $11.9M with participation from Synergy Ventures, Ben Franklin Technology Partners, and Balestier Investments
Debt (2020): $150K led by PPP
Private Equity (2021): $9M supported by Sectoral Asset Management
Series C (2024): $30M featuring Sectoral Asset Management and Blue Ridge Medical Center
Private Equity (2025): $15M backed by Trinity Capital
Private Equity (2026): $24.5M, investors not publicly disclosed
Key Investors in Cagent Vascular
Sectoral Asset Management
Sectoral Asset Management is an investment advisor specializing in managing equities globally within the healthcare sector, with a strong track record in managing biotech equities.
Blue Ridge Medical Center
Blue Ridge Cardiology and Internal Medicine, P.A. specializes in Adult Medicine, offering services in Internal Medicine, Geriatric Medicine and Palliative Care, Cardiology, and Sleep Medicine.
Ben Franklin Technology Partners
Ben Franklin Technology Partners is an organization focused on fostering innovation and technology-based economic development, likely investing in companies with high-growth potential in the technology sector.
What's next for Cagent Vascular?
With the recent major strategic investment and substantial overall financing, Cagent Vascular is poised for significant expansion. The company is likely to focus on scaling its manufacturing capabilities, expanding its commercial reach into new markets, and potentially investing further in research and development to broaden its product pipeline. This strategic capital will enable Cagent Vascular to solidify its market position and continue its mission to improve patient care in vascular interventions, potentially exploring new therapeutic areas or enhancing existing technologies.
See full Cagent Vascular company page
